PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Pacific Biosciences of California, Inc. (PACB)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS69404D1081
CUSIP69404D108
SectorHealthcare
IndustryDiagnostics & Research

Highlights

Market Cap$415.33M
EPS-$1.21
PEG Ratio-0.17
Revenue (TTM)$200.52M
Gross Profit (TTM)$53.47M
EBITDA (TTM)-$287.20M
Year Range$1.25 - $14.55
Target Price$6.08
Short %20.29%
Short Ratio5.76

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Pacific Biosciences of California, Inc.

Popular comparisons: PACB vs. ARDX, PACB vs. ILMN, PACB vs. SPY, PACB vs. CRSP

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Pacific Biosciences of California, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-80.00%-60.00%-40.00%-20.00%0.00%20.00%40.00%NovemberDecember2024FebruaryMarchApril
-79.86%
19.37%
PACB (Pacific Biosciences of California, Inc.)
Benchmark (^GSPC)

S&P 500

Returns By Period

Pacific Biosciences of California, Inc. had a return of -85.02% year-to-date (YTD) and -86.43% in the last 12 months. Over the past 10 years, Pacific Biosciences of California, Inc. had an annualized return of -10.22%, while the S&P 500 had an annualized return of 10.55%, indicating that Pacific Biosciences of California, Inc. did not perform as well as the benchmark.


PeriodReturnBenchmark
Year-To-Date-85.02%6.30%
1 month-60.05%-3.13%
6 months-79.86%19.37%
1 year-86.43%22.56%
5 years (annualized)-27.60%11.65%
10 years (annualized)-10.22%10.55%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
2024-33.64%-15.05%-32.19%
2023-25.98%-25.99%37.22%15.68%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of PACB is 3, indicating that it is in the bottom 3% of the market in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.

The Risk-Adjusted Performance Rank of PACB is 33
Pacific Biosciences of California, Inc.(PACB)
The Sharpe Ratio Rank of PACB is 55Sharpe Ratio Rank
The Sortino Ratio Rank of PACB is 33Sortino Ratio Rank
The Omega Ratio Rank of PACB is 22Omega Ratio Rank
The Calmar Ratio Rank of PACB is 44Calmar Ratio Rank
The Martin Ratio Rank of PACB is 11Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Pacific Biosciences of California, Inc. (PACB) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


PACB
Sharpe ratio
The chart of Sharpe ratio for PACB, currently valued at -0.99, compared to the broader market-2.00-1.000.001.002.003.00-0.99
Sortino ratio
The chart of Sortino ratio for PACB, currently valued at -2.08, compared to the broader market-4.00-2.000.002.004.006.00-2.08
Omega ratio
The chart of Omega ratio for PACB, currently valued at 0.70, compared to the broader market0.501.001.500.70
Calmar ratio
The chart of Calmar ratio for PACB, currently valued at -0.89, compared to the broader market0.001.002.003.004.005.00-0.89
Martin ratio
The chart of Martin ratio for PACB, currently valued at -2.00, compared to the broader market0.0010.0020.0030.00-2.00
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 1.92, compared to the broader market-2.00-1.000.001.002.003.001.92
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 2.78, compared to the broader market-4.00-2.000.002.004.006.002.78
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.33, compared to the broader market0.501.001.501.33
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 1.47, compared to the broader market0.001.002.003.004.005.001.47
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 7.64, compared to the broader market0.0010.0020.0030.007.64

Sharpe Ratio

The current Pacific Biosciences of California, Inc. Sharpe ratio is -0.99. A negative Sharpe ratio means that the risk-free rate is higher than the portfolio's return. This value does not convey any meaningful information.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00NovemberDecember2024FebruaryMarchApril
-0.99
1.92
PACB (Pacific Biosciences of California, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Pacific Biosciences of California, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%NovemberDecember2024FebruaryMarchApril
-97.13%
-3.50%
PACB (Pacific Biosciences of California, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Pacific Biosciences of California, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Pacific Biosciences of California, Inc. was 97.26%, occurring on Apr 16, 2024. The portfolio has not yet recovered.

The current Pacific Biosciences of California, Inc. drawdown is 97.13%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-97.26%Feb 12, 2021798Apr 16, 2024
-93.52%Oct 29, 2010514Nov 13, 20122026Dec 1, 20202540
-22.74%Jan 20, 20216Jan 27, 202110Feb 10, 202116
-11.19%Dec 9, 20207Dec 17, 20202Dec 21, 20209
-10.95%Dec 24, 20203Dec 29, 20206Jan 7, 20219

Volatility

Volatility Chart

The current Pacific Biosciences of California, Inc. volatility is 72.65%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%20.00%40.00%60.00%80.00%NovemberDecember2024FebruaryMarchApril
72.65%
3.58%
PACB (Pacific Biosciences of California, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Pacific Biosciences of California, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items